• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abiomed wins extended Medicare coverage for Impella

Abiomed wins extended Medicare coverage for Impella

August 14, 2019 By Nancy Crotti

AbiomedAbiomed (NSDQ:ABMD) has won a one-year reprieve from a proposed 27% Medicare reimbursement cut to hospitals for the use of its Impella ventricular support device.

In April, the Centers for Medicare & Medicaid Services (CMS) floated the rate cut proposal for inpatient surgeries involving external assist devices inserted into the heart, such as Impella.

The proposed “dramatic decrease” in reimbursement “will result in significant underpayment to hospitals’ treatment of the highest acuity Medicare heart failure patients, such as those suffering from heart attacks leading to cardiogenic shock and heart failure patients being treated with percutaneous coronary intervention,” the company wrote in a letter to CMS. “In addition, we believe this will limit access to care for newly FDA-approved indications for critical heart pumps.”

The FDA decided in May to allow a clinical trial exploring the Impella CP Heart pump’s ability to treat patients undergoing treatment for an ST-segment elevation myocardial infarction, or STEMI heart attack.

Health systems, hospitals and individual cardiologists also responded with letters citing 13 recent changes in American Hospital Association coding that CMS failed to consider in setting its proposed reimbursement rate. The agency also did not take into consideration that 22% of hospitals that used Impella on patients charged for the procedure but not for the device or associated services, which cost about $25,000, according to the Danvers, Mass.-based company.

CMS responded that although it would adopt “a temporary one-time measure” to maintain the fiscal year 2019 reimbursement for Impella and other external cardiac assist devices for FY 2020, which begins October 1, 2019.

“When CMS did its final analysis, it determined this was ‘an outlier circumstance,'” Abiomed said in an email to MassDevice. “The analysis showed 68% of claims contained inaccuracies, with many hospitals not charging for Impella at all. The inaccurate data resulted from an unprecedented level of coding changes over a short period of time.”

 

Filed Under: Business/Financial News, Featured, Hospital Care, Medicare, News Well, Structural Heart Tagged With: Abiomed, Centers for Medicare and Medicaid Services (CMS)

More recent news

  • FDA grants expanded clearance for Levita Magnetics surgical robot
  • FDA adds Gradient denervation tech to advisory program
  • Former Intuitive sales leader joins surgical robot maker Virtual Incision as CEO
  • Smith+Nephew to open first orthopedic ambulatory surgery center in the UK
  • Medtronic partners with IRCAD on Hugo, Affera surgical training

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy